Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Ganagliflozin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ganagliflozin is a once-a-day tablet for type 2 diabetes, developed in China by Huisheng Biopharmaceutical, part of the Sihuan Pharmaceutical group, where it is sold as 惠优静® (Huiyoujing). It lowers blood sugar by helping the kidneys pass extra glucose out in the urine. In medical journals it is often spelled janagliflozin.
China's National Medical Products Administration (NMPA) approved it in January 2024 as a Class 1 innovative drug, to improve blood sugar control in adults with type 2 diabetes:
It is not for type 1 diabetes or diabetic ketoacidosis. It is a prescription diabetes and hormone medicine and should be used under an endocrinologist, diabetologist or physician.
Normally the kidneys filter sugar out of the blood and then take almost all of it back in, using a transporter called SGLT2. Ganagliflozin blocks SGLT2, so the kidneys reabsorb less glucose and more of it leaves the body in the urine. Because this does not depend on insulin, it adds to the effect of other diabetes treatments.
Two phase 3 trials in China, published in Diabetes, Obesity and Metabolism in 2023, support the approval. In 432 adults not controlled by diet and exercise, 24 weeks of treatment lowered HbA1c by 0.80% (25 mg) and 0.88% (50 mg) more than placebo, and about half reached an HbA1c below 7.0% (47.2% and 49.3%, against 23.5%). In 421 adults already taking metformin, adding it lowered HbA1c by 0.58% more than placebo at both doses. People also lost a little weight and saw small falls in systolic blood pressure, and no severe hypoglycaemia occurred over 52 weeks.
Your doctor sets the exact dose based on your blood sugar, kidney tests and other medicines.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Who should not take it: people allergic to the medicine or its ingredients, and people with severe kidney impairment, end-stage kidney disease or on dialysis. It is not recommended if eGFR stays below 30 mL/min/1.73 m².
Other findings: ketones in the urine were seen in 10.0% (25 mg) and 14.1% (50 mg) against 4.3% on placebo, and raised bilirubin in 2.5% on 50 mg. LDL cholesterol rose slightly. It is not recommended during pregnancy or breastfeeding, and safety under 18 years has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets come in 25 mg and 50 mg strengths, in boxes of 7 or 14, so we match the order to the dose your doctor has prescribed. The label says to keep them sealed and below 30°C, and they travel in their original packs under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Endocrinologists in Delhi treat patients from across North India, and our New Delhi dispatch point keeps delivery quick.
Doctors in Mumbai can request the tablets for a named patient, with the strength and quantity matched to the prescription.
Patients in Bangalore can have the medicine delivered to their home or clinic once the prescription and kidney test are checked.
Diabetologists in Chennai can send us the prescription and reports to start the import for their patient.
We plan repeat supplies for patients in Hyderabad so there is no break in once-daily treatment.
Deliveries to Kolkata and the eastern states are scheduled so a new pack arrives before the old one runs out.
Patients in Pune can use the same documented import route, with progress updates shared at each step.
Physicians in Ahmedabad can coordinate access for patients whose doctor has chosen this specific medicine.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating clinic.
Patients in Rajasthan can receive the tablets at home, as long as the import is in their own name.
We arrange delivery for patients treated at public and private diabetes clinics across Uttar Pradesh.
Patients in Kochi and other parts of Kerala can receive regular supplies at their home or clinic.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message